FORMULATION & PROCESS DEVELOPMENT FOR ORAL DOSAGE FORMS
"A 5-Day Modular and Case Study Oriented Training Program"
Historical Location & Reputable Speakers
April 19- 23, 2010, Nassau Inn, New Jersey, USA

NO MORE HARDCOPY HANDOUTS!

A FREE NOTEBOOK PC WITH ELECTRONIC PRESENTATIONS  FOR EVERY ATTENDEE!.

A GROUP OF THREE OR MORE WILL RECEIVE A 10% DISCOUNT.

(SOME OF THE) PHARMACEUTICAL COMPANIES REPRESENTED BY ATTENDEES AT THE PAST EVENTS:
Array BioPharma;  Astellas Pharma. Inc. (JAPAN); AstraZeneca,; Barr Pharmaceuticals;  Bayer HealthCare;, Bayer Schering Pharma (GERMANY); Bristol-Myers Squibb Co.;  CJ Corp (KOREA);  Cubist Pharmaceuticals, Inc.;  Eli Lilly and Company; Frontage laboratories, Inc.;  Gador S.A (ARGENTINA);  Genzyme   (IRELAND); Gilead Sciences Inc.; Impax Laboratories; Intermune; ISP Pharma Systems; Kyowa Pharmaceutical, Inc.; Lannett Company Inc.; MedImmune, Inc.; Merck & Co., Inc.; Neurogen Corporation; Novartis ; Orion Corporation ORION PHARMA (FINLAND); Perrigo Company; Pfizer Pharmaceuticals, LLC; PGM-Pfizer Caguas (PUERTO RICO); Procter & Gamble Pharmaceuticals; Schering Plough Corporation; Schering Plough Research Institute; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals ; Teva Pharmaceuticals Ltd. (ISRAEL); Tunnell Consulting; Tyco Healthcare/Mallinckrodt; Upsher-Smith Laboratories, Inc.; URL/Mutual Pharmaceutical Company; VPS Corporation; Watson Laboratories Inc

 


Innovative Modular Format
Crystal Form of APIs  
Preformulation
 
Formulation & Process Development Guidelines

Milling, Mixing, and Flow 
 
Granulation
 
Tableting/Compaction

Film Coating
 
Technology Transfer 

Stability
 

Critical/Current Issues 
Solubility
Polymorphism
Curriculum Vitae  Stability
Formulation Development Strategies
Selection of excipients
Excipient Functionality Considerations
Process Development Strategies
Scale-Up
Trouble Shooting
Validation
SUPAC
Design Space and other PAT Related Issues

 

 

 

Number of visitors since Jan 2009:  Hit Counter